Greenwich LifeSciences (GLSI) vs Keros Therapeutics (KROS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Keros Therapeutics (KROS) over the past year, gaining 32.3% versus a loss of 27.1%. Over five years, GLSI leads with a -60.1% price change compared with -70.1% for KROS. Keros Therapeutics is the larger company by market cap ($230.8 million vs $222.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | KROS |
|---|---|---|
| Share price | $15.14 | $11.64 |
| Market cap | $222.23M | $230.79M |
| 1-day change | -1.62% | +3.84% |
| YTD return | -27.94% | -42.83% |
| 1-year return | +32.28% | -27.07% |
| 5-year return | -60.12% | -70.15% |
| EPS (TTM) | $-1.53 | $-3.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $22.55 |
| 52-week low | $7.78 | $9.69 |
| Distance from 52-week high | -55.60% | -48.38% |
| Analyst consensus | none | buy |
| Avg. price target upside | +276.49% | +70.36% |
| Average volume | 138.91K | 196.01K |
| Shares outstanding | 14.68M | 19.83M |
| Employees | — | 92 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed KROS by 59.4 percentage points over the past year.
- The two companies sit in different sectors: Greenwich LifeSciences in Healthcare and Keros Therapeutics in Health Care.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Healthcare · Biotechnology
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
GLSI vs KROS FAQ
Which is bigger, Greenwich LifeSciences or Keros Therapeutics?
Keros Therapeutics (KROS) is larger, with a market capitalization of $230.79M compared with $222.23M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, GLSI or KROS?
GLSI returned +32.28% over the past 12 months, compared with -27.07% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Keros Therapeutics in the same industry?
No. Greenwich LifeSciences is in the Healthcare sector, while Keros Therapeutics is in Health Care.